Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of TPEx (Taxotere-platinum-cetuximab) Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (TATIANA)

NCT06640725 is registered in ClinicalTrials.gov with Groupe Oncologie Radiotherapie Tete et Cou as lead sponsor.

NCT NCT06640725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06640725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of TPEx (Taxotere-platinum-cetuximab) Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (TATIANA)
Lead sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Phase
Phase 2
Overall status
Recruiting
Start date
January 2, 2025
Completion date
December 2, 2028
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic squamous cell carcinoma of head and neck